Last update Date/Time:
EU RESPONSE TO COVID-19
Research & Innovation Projects
Combating 2019-nCoV: Advanced Nanobiosensing platforms for POC global diagnostics and surveillance. The project will develop a rapid point-of-care diagnosis and monitoring, and also monitor the evolution of viruses in animals and help prevent future outbreaks. Led by Fundacio Institut Catala de Nanociencia i Nanotecnologia (ES).
• Story: COVID-19 diagnose faster and cheaper
Three Rapid Diagnostic tests (Point-of-Care) for COVID-19 Coronavirus.
European Virus Archive (EVA-Global)
The archive is a virtual collection for human, animal and plant viruses that provides researchers with the necessary material for diagnosing coronavirus infection. Since the start of the crisis EVA-Global has provided over 2200 samples of reference material to researchers in 80 countries. The EU has invested a total of €32.2 million (2009-2023) in this research infrastructure which is led by Université Aix-Marseilles (FR).
HG nCoV19 test
Development and validation of rapid molecular diagnostic test for nCoV19, that does not require virus extraction chemistry, with a particular focus on early stage disease diagnosis. Led by Hibergene Diagnostics (IE).
• Testimonial from Gary Keating (Chief Technology Officer at HiberGene Diagnostics, Dublin)
Value of diagnostics to combat antimicrobial resistance by optimising antibiotic use. This IMI project, led by University Antwerp (BE), aims to transform medical practice by making it easier for doctors to deliver personalised, evidence-based antibiotic prescriptions thanks to the use of innovative diagnostic strategies. The IMI contribution to this project is €6.8 million (2019-2023).
IMI - Innovative Medicines Initiative
On 3 March 2020, the Innovative Medicines Initiative (IMI) supported through the European Commission’s Horizon 2020 Framework Programme for Research and Innovation, launched a special fast-track call for the “Development of therapeutics and diagnostics combatting coronavirus infections” with an EU contribution of €45 million, which was subsequently increased to €72 million. On 12 May 2020, following the independent evaluation of proposals, it was announced that 8 projects were short-listed for funding, including on 5 projects receiving €28 million in EU grants to develop rapid diagnostics:
COVID-RED - COVID-19 (NL)
infections: remote early detection. The project will combine expertise in clinical epidemiology with digital devices (such as wearables and mobile apps) to rapidly and reliably detect cases, so that patients can be prioritised for testing. Led by Universitair Medisch Centrum Utrecht (NL)
A miniaturised disposable molecular diagnostics platform for combatting coronavirus infections. This low-cost, diagnostic system that will make it possible to test patients with laboratory quality performance almost anywhere in 15 minutes or less. Led by GNA Biosolutions (DE)
Rapid and secure AI imaging based diagnosis, stratification, follow-up, and preparedness for coronavirus pandemics.
The project aims to deliver a decision support system for improved and more rapid diagnosis and prognosis. Citizens and patients will be involved in the development of the system. Led by Oncoradiomics (BE)
Evaluation of a production ready portable, point-of-need platform, direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection. The project aims to develop a simple test with results in just 40 minutes and create the capacity to rapidly deploying new tests in response to future outbreaks. Led by BG Research (UK).
Robust automation and point of care identification of COVID for a diagnostic test that can simultaneously detect SARS-CoV-2, as well as 30 other common respiratory bacteria and viruses, to ensure patients are quickly isolated and that all patients receive the right treatment. Led by GeneFirst (UK)
Viral Metagenomics for Innovation value, the project exploits environmental metagenomes with a focus on viral genomes in specific ecosystems. Sequencing technology, bioinformatics solutions and specific products for biotechnical applications developed by the project partners can be applied to detection and research on coronavirus. The project, which is led by MATIS OHF (Iceland), received €8 million (2016-2020).
Brussels - Milano - Nice - Tokyo
Avenue Louise, 367
Bld. Franck Pilatte, 19 bis
YONO HOUSE 9-1 KAMIOCHIAI, SAITAMA-SHI, SAITAMA-KEN
〒 338-0001 JAPAN
Via S. Veniero 6